结肠镜后结直肠癌以锯齿状分子特征为主:系统综述与荟萃分析
该系统综述与荟萃分析纳入15项研究、11个队列,比较2143例结肠镜后结直肠癌(PCCRC)与19036例散发性结直肠癌(SCRC)的分子特征。PCCRC更常表现为MSI、CIMP和BRAF突变,KRAS突变较少,提示其更倾向锯齿状通路;PCCRC生存与SCRC相似,但劣于筛查检出癌。
要点
- PCCRC较SCRC更常见MSI、CIMP和BRAF突变,KRAS突变较少。
- PCCRC病变更偏近端,患者年龄更大,MSI与BRAF突变及近端病变强相关。
- PCCRC生存与SCRC相似,但劣于筛查检出癌;应加强锯齿状病变检测。
核心结论
- PCCRC的临床和分子特征更符合锯齿状通路而非散发性癌通路。
- 加强临床显著锯齿状病变的检测可能提高结直肠癌筛查效果。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library自建库至2024年4月。
- 纳入15项研究、11个队列,含2143例PCCRC和19036例SCRC。
主要发现
- PCCRC较SCRC患者年龄更大(标准化均数差0.29,95%CI 0.20-0.38),病变更偏近端(OR 2.08,95%CI 1.91-3.63)。
- PCCRC较SCRC更常表现MSI(OR 2.28,95%CI 1.69-3.08)、CIMP(OR 2.10,95%CI 1.39-3.18)和BRAF突变(OR 1.74,95%CI 1.22-2.49),KRAS突变较少(OR 0.63,95%CI 0.45-0.87)。
- 合并分析中MSI与BRAF突变强相关(OR 9.36,95%CI 5.11-17.16),与近端病变强相关(OR 6.16,95%CI 3.74-10.16)。
- PCCRC与SCRC的5年总生存相似(HR 1.03,95%CI 0.64-1.66),但PCCRC生存劣于筛查检出癌(HR 1.65,95%CI 1.46-1.86)。
临床怎么用
- 对PCCRC应关注锯齿状通路相关分子特征(MSI、CIMP、BRAF突变)。
- 结肠镜检查中应加强临床显著锯齿状病变的检出,以提升筛查效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Postcolonoscopy colorectal cancers (PCCRCs) are an adverse outcome associated with missed lesions and incomplete polypectomy. However, their molecular features have not been systematically reviewed. METHODS: We searched PubMed, Embase, and Cochrane Library databases from inception to April 2024. Studies examining the molecular characteristics of PCCRCs, including microsatellite instability (MSI), CpG island methylation phenotype (CIMP), genetic mutations, and chromosomal alterations were regarded as eligible. RESULTS: In total, 15 studies encompassing 11 cohorts, with 2,143 PCCRC and 19,036 sporadic colorectal cancer (SCRC) cases, were analyzed. Compared with SCRC, PCCRC was associated with older age (standardized mean difference 0.29, 95% confidence interval [CI] 0.20-0.38) and more proximal lesions (odds ratio [OR] 2.08, 95% CI 1.91-3.63). Molecularly, PCCRCs were more likely to exhibit MSI (OR 2.28, 95% CI 1.69-3.08), CIMP (OR 2.10, 95% CI 1.39-3.18), and BRAF mutations (OR 1.74, 95% CI 1.22-2.49) but were less likely to exhibit KRAS mutations (OR 0.63, 95% CI 0.45-0.87). Furthermore, MSI was strongly correlated with BRAF mutation (OR 9.36, 95% CI 5.11-17.16) and proximal lesions (OR 6.16, 95% CI 3.74-10.16) in a pooled analysis. Although the pooled 5-year overall survival rate was similar between PCCRC and SCRC cases (hazard ratio 1.03, 95% CI 0.64-1.66), PCCRCs exhibited worse survival compared with screening-detected ones (hazard ratio 1.65, 95% CI 1.46-1.86). DISCUSSION: Clinical and molecular features indicate that PCCRCs are more likely to be associated with the serrated pathway than with SCRC. Enhancing the detection of clinically significant serrated lesions may improve the efficacy of CRC screening.
引用
- Yeh JH, Moi SH, Chen CC, et al. Predominant Serrated Molecular Signature in Postcolonoscopy Colorectal Cancer: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. PMID: 40699236. doi:10.14309/ajg.0000000000003658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。